NOME portfolio company Sedivention has closed a €2.9 million seed financing round to further develop its minimally invasive, outpatient therapy for the treatment of obesity. The round includes participation from High‑Tech Gründerfonds (HTGF) alongside other investors, and will support continued product development and the generation of initial clinical data ahead of market entry.
Sedivention is developing a one‑time, cryo‑based intervention designed to reduce feelings of hunger by targeting the gastric branches of the vagus nerve. The procedure is intended to be performed on an outpatient basis and does not involve surgery, implants, or lifelong medication. The approach aims to address disrupted hunger and satiety regulation, which is a key physiological factor in obesity.
With the new funding, the company plans to further advance its technology, complete product development, and prepare for the next clinical and regulatory steps, including early human studies.
Sedivention is part of the NOME program, where the team has worked with experienced mentors to strengthen its business strategy and navigate key scientific, clinical, and commercial milestones. The company is based in Germany and operates within the medical devices space.